Corporate presentation
Logotype for Inogen Inc

Inogen (INGN) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Inogen Inc

Corporate presentation summary

6 Nov, 2026

Strategic positioning

  • Transitioning from a single-product oxygen business to a respiratory care platform spanning oxygen, airway clearance, sleep therapy, and digital solutions.

  • Strategic priorities: drive top-line growth, advance profitability, and expand the innovation pipeline.

  • Portfolio expansion targets COPD, bronchiectasis, and sleep apnea, with an estimated ~70 million U.S. patients across these conditions.

  • Existing advantages include POC technology, brand recognition, physician confidence, and established distributor relationships.

Markets and product expansion

  • Estimated U.S. addressable markets: $0.4B for POCs, $0.3B for stationary oxygen concentrators, $2.2B for CPAP masks and accessories, and $0.5B for airway clearance.

  • Voxi 5 launched in Q2 2025, adding an estimated $300M to the oxygen addressable market; it serves stationary oxygen users, who represent 90% of LTOT patients.

  • Aurora CPAP masks launched in Q1 2026 into a U.S. market estimated at $2.2B, with high-single-digit growth and 20–30% patient overlap with COPD.

  • Simeox 200 received FDA clearance in Q4 2024; airway clearance targets an estimated $500M U.S. bronchiectasis market as reimbursement advances.

  • POC share of ambulatory oxygen new patient starts rose from 38% in 2019 to 41% in 2025; tanks retained 59% share in 2025, with ~350,000 patients starting on tanks annually.

Financial performance

  • FY25 revenue was $349M, gross margin 44.2%, adjusted EBITDA $2.7M, and adjusted net loss $8.0M; cash, equivalents, marketable securities and restricted cash totaled $121M, with no debt, as of Dec. 31, 2025.

  • Revenue increased from $316M in FY23 to $336M in FY24 and $349M in FY25; 7 of the last 8 quarters delivered mid-single-digit revenue growth.

  • Operating loss improved from $109M in FY23 to $43M in FY24 and $30M in FY25; net loss improved from $102M to $36M and $23M over the same years.

  • Adjusted EBITDA improved from a loss of $37.8M in FY23 to a loss of $9.5M in FY24 and income of $2.7M in FY25, the first positive result since 2021.

  • FY25 revenue mix: U.S. sales 45%, international sales 40%, and U.S. rentals 15%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Inogen